Fate Therapeutics, Inc.
FATE
$1.90
-$0.01-0.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -52.64% | -51.24% | -46.92% | -31.23% | 105.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -52.64% | -51.24% | -46.92% | -31.23% | 105.85% |
| Cost of Revenue | -25.89% | -23.41% | -14.13% | -3.76% | -30.34% |
| Gross Profit | 20.99% | 18.39% | 8.25% | -0.71% | 37.87% |
| SG&A Expenses | -31.57% | -32.31% | -26.73% | -13.99% | -12.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.35% | -26.73% | -20.43% | -10.45% | -9.29% |
| Operating Income | 25.53% | 25.03% | 18.62% | 9.14% | 12.79% |
| Income Before Tax | 26.14% | 26.82% | 12.42% | 2.39% | 7.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.14% | 26.82% | 12.42% | 2.39% | 7.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.14% | 26.82% | 12.42% | 2.39% | 7.46% |
| EBIT | 25.53% | 25.03% | 18.62% | 9.14% | 12.79% |
| EBITDA | 25.22% | 24.28% | 18.15% | 8.35% | 13.29% |
| EPS Basic | 26.97% | 30.42% | 20.26% | 14.93% | 22.13% |
| Normalized Basic EPS | 20.96% | 25.31% | 30.01% | 24.54% | 32.21% |
| EPS Diluted | 26.97% | 30.42% | 20.26% | 14.93% | 22.13% |
| Normalized Diluted EPS | 20.96% | 25.31% | 30.01% | 24.54% | 32.21% |
| Average Basic Shares Outstanding | 1.14% | 4.63% | 8.91% | 13.64% | 18.84% |
| Average Diluted Shares Outstanding | 1.14% | 4.63% | 8.91% | 13.64% | 18.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |